1. Home
  2. HTBK vs PHAT Comparison

HTBK vs PHAT Comparison

Compare HTBK & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTBK
  • PHAT
  • Stock Information
  • Founded
  • HTBK 1997
  • PHAT 2018
  • Country
  • HTBK United States
  • PHAT United States
  • Employees
  • HTBK N/A
  • PHAT N/A
  • Industry
  • HTBK Major Banks
  • PHAT Biotechnology: Pharmaceutical Preparations
  • Sector
  • HTBK Finance
  • PHAT Health Care
  • Exchange
  • HTBK Nasdaq
  • PHAT Nasdaq
  • Market Cap
  • HTBK 588.2M
  • PHAT 640.9M
  • IPO Year
  • HTBK 1998
  • PHAT 2019
  • Fundamental
  • Price
  • HTBK $9.30
  • PHAT $9.74
  • Analyst Decision
  • HTBK Buy
  • PHAT Strong Buy
  • Analyst Count
  • HTBK 3
  • PHAT 5
  • Target Price
  • HTBK $11.33
  • PHAT $16.40
  • AVG Volume (30 Days)
  • HTBK 660.9K
  • PHAT 1.0M
  • Earning Date
  • HTBK 07-24-2025
  • PHAT 08-07-2025
  • Dividend Yield
  • HTBK 5.58%
  • PHAT N/A
  • EPS Growth
  • HTBK N/A
  • PHAT N/A
  • EPS
  • HTBK 0.63
  • PHAT N/A
  • Revenue
  • HTBK $180,089,000.00
  • PHAT $114,039,000.00
  • Revenue This Year
  • HTBK $10.40
  • PHAT $194.40
  • Revenue Next Year
  • HTBK $7.12
  • PHAT $103.23
  • P/E Ratio
  • HTBK $14.79
  • PHAT N/A
  • Revenue Growth
  • HTBK 3.15
  • PHAT 1049.82
  • 52 Week Low
  • HTBK $8.09
  • PHAT $2.21
  • 52 Week High
  • HTBK $11.27
  • PHAT $19.71
  • Technical
  • Relative Strength Index (RSI)
  • HTBK 37.39
  • PHAT 61.57
  • Support Level
  • HTBK $9.27
  • PHAT $8.03
  • Resistance Level
  • HTBK $9.56
  • PHAT $10.09
  • Average True Range (ATR)
  • HTBK 0.24
  • PHAT 0.66
  • MACD
  • HTBK -0.07
  • PHAT 0.06
  • Stochastic Oscillator
  • HTBK 21.05
  • PHAT 85.89

About HTBK Heritage Commerce Corp

Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two reportable segments, namely Banking and Factoring. A majority of its revenue is generated from the Banking segment, which provides various loan products, including commercial and industrial loans, commercial real estate loans, construction loans, etc. This segment also focuses on deposit generation on relationship accounts, encompassing non-interest bearing demand, interest bearing demand, money market accounts, certificates of deposit, and savings accounts.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: